Stada has delivered a solid performance in 2022 that has seen the German generics giant’s financials lifted in particular by a consumer healthcare segment that has now become the largest of the firm’s three business segments.
“With a 17% increase in adjusted sales to €1.62bn, Consumer Healthcare became Stada’s largest business unit in 2022, accounting for 43% of group turnover,” the company reported, citing “a combination of organic growth and the successful integration of recent acquisitions” as driving a “strong performance, well ahead of market averages